AR084473A1 - Composiciones farmaceuticas de (r) 1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropanecarboxamida - Google Patents

Composiciones farmaceuticas de (r) 1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropanecarboxamida

Info

Publication number: AR084473A1
Authority: AR; Argentina
Prior art keywords: difluorobenzo; cyclopropanecarboxamide; methylpropan; dioxol; indol
Prior art date: 2010-08-23

Application number

Other languages

English (en)

Spanish (es)

Inventor

Rossitza Gueorguieva Alargova

Craig Antony Dunbar

Irina Nikolaevna Kadiyala

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-23

Filing date

2011-08-23

Publication date

2013-05-22

2011-08-23 Application filed by Vertex Pharma filed Critical Vertex Pharma

2013-05-22 Publication of AR084473A1 publication Critical patent/AR084473A1/es

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 3
AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 title 1
MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 abstract 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 1
201000003883 Cystic fibrosis Diseases 0.000 abstract 1
229940125904 compound 1 Drugs 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000007884 disintegrant Substances 0.000 abstract 1
239000000945 filler Substances 0.000 abstract 1
102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical group C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Psychology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)

ARP110103065 2010-08-23 2011-08-23 Composiciones farmaceuticas de (r) 1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropanecarboxamida AR084473A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37597610P	2010-08-23	2010-08-23
US201161506220P	2011-07-11	2011-07-11

Publications (1)

Publication Number	Publication Date
AR084473A1 true AR084473A1 (es)	2013-05-22

Family

ID=45594557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP110103065 AR084473A1 (es)	2010-08-23	2011-08-23	Composiciones farmaceuticas de (r) 1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropanecarboxamida

Country Status (13)

Country	Link
US (1)	US20120046330A1 (2)
EP (1)	EP2608779A2 (2)
JP (1)	JP2013536231A (2)
CN (1)	CN103153287A (2)
AR (1)	AR084473A1 (2)
AU (2)	AU2011293658B2 (2)
BR (1)	BR112013004443A8 (2)
CA (1)	CA2808501A1 (2)
MX (1)	MX2013002035A (2)
NZ (1)	NZ606805A (2)
RU (1)	RU2013112937A (2)
TW (2)	TWI619515B (2)
WO (1)	WO2012027247A2 (2)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200602755B (en)	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
LT2502911T (lt)	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
ATE512145T1 (de)	2005-08-11	2011-06-15	Vertex Pharma	Modulatoren des cystic fibrosis transmembrane conductance regulators
EP1945632B1 (en)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2006336504C9 (en)	2005-12-28	2015-05-14	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8563573B2 (en) *	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US8969386B2 (en)	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
HUE028426T2 (en)	2007-08-24	2016-12-28	Vertex Pharma	Isothiazolopyridinones for (inter alia) treating cystic fibrosis
SI2217572T1 (sl) *	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2639224B1 (en)	2007-12-07	2016-08-24	Vertex Pharmaceuticals Incorporated	Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
WO2009076141A2 (en) *	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2271621B1 (en)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
JP2012504143A (ja) *	2008-09-29	2012-02-16	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
NZ592685A (en) *	2008-10-23	2013-04-26	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
SI2408750T1 (sl)	2009-03-20	2015-11-30	Vertex Pharmaceuticals Incorporated	Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
US20110251253A1 (en) *	2010-03-25	2011-10-13	Vertex Pharmaceuticals Incorporated	Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20160682T1 (hr)	2010-04-07	2016-07-29	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
ES2608474T3 (es) *	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
IN2014KN00885A (2)	2011-11-08	2015-10-02	Vertex Pharma
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (en)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2013270681A1 (en) *	2012-06-08	2014-12-18	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of CFTR -mediated disorders
WO2014014841A1 (en) *	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2895150A1 (en)	2012-09-11	2015-07-22	Bend Research, Inc.	Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
EP2970468B1 (en)	2013-03-13	2021-07-07	Novartis AG	Notch2 binding molecules for treating respiratory diseases
JP6963896B2 (ja)	2013-11-12	2021-11-10	バーテックスファーマシューティカルズインコーポレイテッドVertex Pharmaceuticals Incorporated	Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
EP3090749B1 (en)	2013-12-20	2023-08-30	Daicel Corporation	Nutrient composition having lipid metabolism-improving action
EP3091981B1 (en) *	2014-01-09	2021-03-10	Verastem, Inc.	Compositions and methods for treatment of abnormal cell growth
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
EP2932966A1 (en)	2014-04-16	2015-10-21	Novartis AG	Gamma secretase inhibitors for treating respiratory diseases
TWI735416B (zh)	2014-10-06	2021-08-11	美商維泰克斯製藥公司	囊腫纖維化症跨膜傳導調節蛋白之調節劑
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
PT3221692T (pt)	2014-11-18	2021-09-10	Vertex Pharma	Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
EP3240539A4 (en)	2014-12-31	2018-07-25	Auspex Pharmaceuticals, Inc.	Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
HK1249893A1 (zh)	2015-03-31	2018-11-16	Vertex Pharmaceuticals (Europe) Limited	氘代vx-661
US10047077B2 (en)	2016-04-13	2018-08-14	Skyline Antiinfectives, Inc.	Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
MX392941B (es) *	2016-09-07	2025-03-24	Celgene Corp	Composiciones para comprimidos.
SI3519401T1 (sl)	2016-09-30	2022-01-31	Vertex Pharmaceuticals Incorporated	Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
CN110267948B (zh)	2016-12-09	2023-12-08	弗特克斯药品有限公司	囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
TWI799435B (zh)	2017-08-02	2023-04-21	美商維泰克斯製藥公司	製備化合物之製程
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko)	2017-12-08	2024-10-14	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) *	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
AU2019222758B2 (en)	2018-02-15	2022-07-07	Vertex Pharmaceuticals Incorporated	Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
EP3774825A1 (en)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CA3067611A1 (en)	2019-01-15	2020-07-15	Apotex Inc.	Processes for the preparation of tezacaftor and intermediates thereof
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
US12576033B2 (en)	2019-04-11	2026-03-17	Gfb (Abc), Llc	Spray-dried formulation of a pyridazinone TRPC5 inhibitor
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
CA3150162A1 (en)	2019-08-14	2021-02-18	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
CN111346062A (zh) *	2020-03-11	2020-06-30	左人杰	一种以复合钙盐增加主药稳定性的口崩片及其制备方法
TWI905184B (zh) *	2020-05-08	2025-11-21	比利時商健生藥品公司	用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌
WO2022013360A1 (en) *	2020-07-17	2022-01-20	Synthon B.V.	Pharmaceutical composition comprising ivacaftor
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en)	2020-08-13	2023-04-01	Vertex Pharma	Crystal forms of CFTR modulators
EP4225762A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en)	2020-12-10	2023-07-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
AU2003277162C1 (en)	2002-09-30	2009-12-24	The Regents Of The University Of California	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2004080972A1 (en)	2003-03-12	2004-09-23	Vertex Pharmaceuticals Incorporated	Pirazole modulators of atp-binding cassette transporters
HUE047569T2 (hu)	2003-04-11	2020-04-28	Ptc Therapeutics Inc	1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
US7696244B2 (en)	2003-05-16	2010-04-13	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
EP1646615B1 (en)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
MXPA06004005A (es)	2003-10-08	2006-06-28	Vertex Pharma	Moduladores de transportadores con casete de union con atp.
JP4869072B2 (ja)	2003-11-14	2012-02-01	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
BRPI0509282A (pt)	2004-03-30	2007-09-18	Univ California	compostos contendo hidrazida inibidores de cftr e seus usos
US20050222271A1 (en) *	2004-03-31	2005-10-06	Le Huang	Novel amorphous form of memantine hydrochloride
AU2005251745A1 (en)	2004-06-04	2005-12-22	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
EP2402323A3 (en)	2004-10-13	2012-05-30	PTC Therapeutics, Inc.	Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
EP2363128B1 (en)	2005-03-11	2016-02-17	Vertex Pharmaceuticals Incorporated	Indole modulators of ATP-binding cassette transporters
CA2600869A1 (en)	2005-03-18	2006-09-28	The Regents Of The University Of California	Compounds having activity in correcting mutant-cftr processing and uses thereof
PT2402002T (pt)	2005-04-08	2018-10-08	Ptc Therapeutics Inc	Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
EP1891018B1 (en)	2005-05-24	2011-11-16	Vertex Pharmaceuticals, Inc.	Modulators of atp-binding cassette transporters
AU2006302371A1 (en)	2005-10-06	2007-04-19	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding cassette transporters
WO2007079139A2 (en) *	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
NZ571803A (en) *	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
US7645789B2 (en) *	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
JP2012504143A (ja) *	2008-09-29	2012-02-16	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
UA104876C2 (uk)	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
EP2365972B1 (en) *	2008-11-06	2014-12-17	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
CA2796642A1 (en) *	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof

2011
- 2011-08-22 CA CA2808501A patent/CA2808501A1/en not_active Abandoned
- 2011-08-22 MX MX2013002035A patent/MX2013002035A/es not_active Application Discontinuation
- 2011-08-22 US US13/214,419 patent/US20120046330A1/en not_active Abandoned
- 2011-08-22 JP JP2013526057A patent/JP2013536231A/ja active Pending
- 2011-08-22 EP EP11751753.2A patent/EP2608779A2/en not_active Withdrawn
- 2011-08-22 AU AU2011293658A patent/AU2011293658B2/en not_active Ceased
- 2011-08-22 WO PCT/US2011/048565 patent/WO2012027247A2/en not_active Ceased
- 2011-08-22 BR BR112013004443A patent/BR112013004443A8/pt not_active Application Discontinuation
- 2011-08-22 CN CN2011800511228A patent/CN103153287A/zh active Pending
- 2011-08-22 NZ NZ60680511A patent/NZ606805A/en not_active IP Right Cessation
- 2011-08-22 RU RU2013112937/15A patent/RU2013112937A/ru not_active Application Discontinuation
- 2011-08-23 AR ARP110103065 patent/AR084473A1/es not_active Application Discontinuation
- 2011-08-23 TW TW103137082A patent/TWI619515B/zh active
- 2011-08-23 TW TW100130218A patent/TW201238611A/zh unknown
2015
- 2015-06-03 AU AU2015202975A patent/AU2015202975B2/en not_active Ceased

Also Published As

Publication number	Publication date
TW201503911A (zh)	2015-02-01
EP2608779A2 (en)	2013-07-03
MX2013002035A (es)	2013-03-25
BR112013004443A8 (pt)	2018-01-02
JP2013536231A (ja)	2013-09-19
NZ606805A (en)	2015-03-27
BR112013004443A2 (pt)	2016-06-07
CN103153287A (zh)	2013-06-12
AU2011293658A1 (en)	2013-04-04
TWI619515B (zh)	2018-04-01
CA2808501A1 (en)	2012-03-01
AU2011293658B2 (en)	2015-03-05
WO2012027247A2 (en)	2012-03-01
TW201238611A (en)	2012-10-01
AU2015202975A1 (en)	2015-06-18
US20120046330A1 (en)	2012-02-23
WO2012027247A3 (en)	2012-05-24
AU2015202975B2 (en)	2016-05-12
RU2013112937A (ru)	2014-09-27

Publication	Publication Date	Title
AR084473A1 (es)	2013-05-22	Composiciones farmaceuticas de (r) 1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropanecarboxamida
HK1209318A1 (en)	2016-04-01	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CY1124852T1 (el)	2022-11-25	Φαρμακευτικες συνθεσεις 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλ) κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλπυριδιν-2-υλ)βενζοϊκου οξεος και χορηγηση αυτων
CY1122197T1 (el)	2020-11-25	ΣΚΕΥΑΣΜΑΤΑ 3-(6-(1-(2.2-ΔΙΦΘΟΡΟΒΕΝΖΟ[D][1,3]ΔΙΟΞΟΛ-5-Υλ) ΚΥΚΛΟΠΡΟΠΑΝΟΚΑΡΒΟΞΑΜΙΔΟ)-3-ΜΕΘΥΛΠΥΡΙΔΙΝ-2-Υλ)ΒΕΝΖΟΪΚΟΥ ΟΞΕΟΣ
NI201100158A (es)	2012-01-24	Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona
EA201490228A1 (ru)	2014-08-29	Новые производные трифторметилоксадиазола и их применение для лечения заболевания
DOP2014000265A (es)	2015-01-31	Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
CU24091B1 (es)	2015-04-29	Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden
EA201491060A1 (ru)	2014-09-30	Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201070597A1 (ru)	2010-12-30	Антибактериальные аналоги аминогликозида
CR10802A (es)	2009-07-13	COMPUESTOS TETRAHIDROCICLOPENTA[b]INDOL COMO MODULARES DEL RECEPTOR ANDROGENO
AR079208A2 (es)	2012-01-04	Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
CL2013000714A1 (es)	2013-10-11	Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
AR060019A1 (es)	2008-05-21	Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
ECSP11011073A (es)	2011-06-30	Nuevas lactamas como inhibidores de beta secretasa
MX2014003261A (es)	2014-04-10	Formulaciones de acido ciclopropancarboxilico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida.
CY1111442T1 (el)	2015-08-05	Ενωσεις πιπεριδινης και χρησεις αυτων
MX391620B (es)	2025-03-19	Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
BR112015010271A8 (pt)	2019-10-01	produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
MX2018005625A (es)	2018-12-06	Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales.
CO6640318A2 (es)	2013-03-22	Formas de dosificación oral de bendamustina
CO6440558A2 (es)	2012-05-15	Composiciones farmacéuticas de rendimiento de producto y cumplimiento del paciente superiores
MX2012004337A (es)	2012-08-31	Formulaciones en aerosol medicinales mejoradas.
UY33468A (es)	2012-01-31	Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal
CU20140134A7 (es)	2015-03-30	Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa

Legal Events

Date	Code	Title	Description
2021-06-24	FC	Refusal